+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alzheimer's Disease Drugs Market by Drug Class (Amyloid Beta-Targeting Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonists), Drug Type (Branded Drugs, Generic Drugs), Formulation, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Alzheimer's Disease Drugs Market by Drug Class (Amyloid Beta-Targeting Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonists), Drug Type (Branded Drugs, Generic Drugs), Formulation, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Alzheimer's Disease Drugs Market by Drug Class (Amyloid Beta-Targeting Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonists), Drug Type (Branded Drugs, Generic Drugs), Formulation, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4905145
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Alzheimer’s Disease Drugs Market is at a critical juncture, shaped by accelerated drug development and intensifying demand for advanced therapies to address growing cognitive health needs across aging populations worldwide.

Market Snapshot: Alzheimer’s Disease Drugs Market Growth

The Alzheimer’s Disease Drugs Market grew from USD 4.74 billion in 2024 to USD 5.22 billion in 2025. It is expected to continue growing at a CAGR of 10.14%, reaching USD 8.46 billion by 2030. This trajectory reflects surging demand for disease-modifying drugs and consistent investment in innovative therapeutic platforms. Expansion is reinforced by an aging global population, heightened prevalence rates, and the prioritization of Alzheimer’s research within public health agendas.

Scope & Segmentation of the Alzheimer’s Disease Drugs Market

This research provides a comprehensive analysis of the Alzheimer’s Disease Drugs Market landscape, examining the diverse range of products, distribution frameworks, end-user groups, and regional developments.

  • Drug Class: Amyloid beta-targeting agents (including antibodies and beta-secretase/BACE inhibitors), cholinesterase inhibitors, NMDA receptor antagonists
  • Drug Type: Branded drugs and generic drugs
  • Formulation: Injectable (intravenous infusion, subcutaneous injection) and oral (capsule, tablet) options
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies
  • End User: Clinics, homecare providers, hospitals
  • Geographical Coverage:
    • Americas (United States, including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina)
    • Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland)
    • Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: Eisai Co., Ltd.; AbbVie Inc.; Novartis AG; Johnson & Johnson; Biogen Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; Viatris Inc.; Apotex Inc.

Key Takeaways for Senior Decision-Makers

  • Market momentum is driven by a shift toward mechanism-based therapies, leveraging immunotherapy innovations and precision medicine for earlier, more effective intervention in Alzheimer’s disease progression.
  • Digital biomarker technologies are supporting earlier diagnosis and more reliable tracking of patient response, improving trial outcomes and clinical monitoring in real-world settings.
  • Regulatory frameworks are evolving, introducing accelerated approval and real-world evidence models that are reshaping product development and post-market evaluation.
  • Collaboration among large pharma, biotech innovators, and academic institutions is intensifying, expediting the transition of drug candidates from research to clinical trials and commercialization.
  • Strategic pricing and access strategies are increasingly crucial as market expansion interfaces with cost-sensitive healthcare systems and patient payor networks.
  • Regional differences in regulatory and reimbursement environments are influencing the pace and scale of therapy adoption, requiring localization of go-to-market and commercialization strategies.

Tariff Impact: Pharmaceutical Trade Policy and Market Resilience

New tariff measures on pharmaceutical imports in the United States since 2025 are introducing additional cost pressures for manufacturers and developers. These changes are prompting a reorganization of supply chains through sourcing adjustments and nearshoring strategies. As a result, companies must manage higher logistics expenses and redesign value chains to ensure both patient access and operational resilience amid evolving trade dynamics.

Methodology & Data Sources

This analysis is grounded in expert interviews with neuroscientists, regulatory specialists, and industry executives. It draws on systematic literature review, patent analysis, and regulatory filings to validate market trends and pipeline milestones. Findings are corroborated using data triangulation and peer advisory reviews throughout the research process.

Why This Report Matters

  • Delivers actionable intelligence on competitive, regulatory, and technological drivers shaping short- and long-term strategy in Alzheimer’s therapy markets.
  • Assists C-suite leaders and strategic planners in evaluating investment, partnership, and product development opportunities within a rapidly changing landscape.

Conclusion

The Alzheimer’s Disease Drugs Market is evolving through a convergence of scientific, regulatory, and strategic advances. Industry leaders equipped with these insights can proactively navigate challenges and capitalize on emerging opportunities.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Implementation of blood-based biomarkers for early detection and trial enrichment in Alzheimer’s drug development
5.2. Escalating pricing debates and reimbursement pathway complexities for novel anti-amyloid antibody therapies
5.3. Integration of digital cognitive assessment tools and remote patient monitoring in clinical trials for Alzheimer’s drugs
5.4. Advances in tau-targeting small molecule inhibitors with improved blood-brain barrier penetration profiles
5.5. Emerging combination regimens targeting neuroinflammation and synaptic repair mechanisms in Alzheimer’s therapy pipelines
5.6. Growing role of AI and machine learning platforms in predicting therapeutic efficacy and optimizing trial design
5.7. Development of gene-editing approaches targeting APOE4 allele carriage to reduce Alzheimer’s disease risk profiles
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Alzheimer's Disease Drugs Market, by Drug Class
8.1. Introduction
8.2. Amyloid Beta-Targeting Agents
8.2.1. Amyloid Beta Antibodies
8.2.2. Beta-Secretase (BACE) Inhibitors
8.3. Cholinesterase Inhibitors
8.4. NMDA Receptor Antagonists
9. Alzheimer's Disease Drugs Market, by Drug Type
9.1. Introduction
9.2. Branded Drugs
9.3. Generic Drugs
10. Alzheimer's Disease Drugs Market, by Formulation
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous Infusion
10.2.2. Subcutaneous Injection
10.3. Oral
10.3.1. Capsule
10.3.2. Tablet
11. Alzheimer's Disease Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Alzheimer's Disease Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
13. Americas Alzheimer's Disease Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Alzheimer's Disease Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Alzheimer's Disease Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eisai Co., Ltd.
16.3.2. AbbVie Inc.
16.3.3. Novartis AG
16.3.4. Johnson & Johnson
16.3.5. Biogen Inc.
16.3.6. Eli Lilly and Company
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.8. Sandoz International GmbH
16.3.9. Viatris Inc.
16.3.10. Apotex Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ALZHEIMER'S DISEASE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ALZHEIMER'S DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ALZHEIMER'S DISEASE DRUGS MARKET: RESEARCHAI
FIGURE 26. ALZHEIMER'S DISEASE DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. ALZHEIMER'S DISEASE DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. ALZHEIMER'S DISEASE DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ALZHEIMER'S DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BETA-SECRETASE (BACE) INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BETA-SECRETASE (BACE) INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 100. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 101. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 102. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 103. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 108. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 109. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 110. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 111. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 116. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 117. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 126. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 127. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 200. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 201. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 206. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 208. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 209. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 216. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 217. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 222. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 224. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 225. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 246. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 247. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 248. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 249. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 250. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 251. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 252. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 253. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 254. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 255. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 256. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 257. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 262. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 263. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 264. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 265. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 266. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 270. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 271. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 272. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 273. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA-TARGETING AGENTS, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFR

Samples

Loading
LOADING...

Companies Mentioned

  • Eisai Co., Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biogen Inc.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Apotex Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.46 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Alzheimer's Disease Drugs - Global Strategic Business Report - Product Image

Alzheimer's Disease Drugs - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Alzheimer's Therapeutics Market by Therapy Type, Mechanism Of Action, Formulation, Delivery Mode, Distribution Channel, End User, Disease Stage - Global Forecast 2025-2030 - Product Image

Alzheimer's Therapeutics Market by Therapy Type, Mechanism Of Action, Formulation, Delivery Mode, Distribution Channel, End User, Disease Stage - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Blood Tests for Alzheimer's Diagnosis Market by Product Type, Technology, Sample Type, End User, Disease Stage, Application - Global Forecast 2025-2030 - Product Image

Blood Tests for Alzheimer's Diagnosis Market by Product Type, Technology, Sample Type, End User, Disease Stage, Application - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Alzheimer's Drugs - A Global Market Overview - Product Image

Alzheimer's Drugs - A Global Market Overview

  • Report
  • 253 Pages
  • Global
From
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Alzheimer's Disease Drugs Market

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone. The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.